Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $57

Benzinga Newsdesk www.benzinga.com Negative 60.1%

Neg 60.1% Neu 0% Pos 0%

Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $62 to $57.